GlassScriptPhysician profile
Andrew C Caldwell
NPI 1184041345
$11,755.09
in general payments reported to CMS, 2019-2025
65 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,843 · 2020: $1,475 · 2021: $1,912 · 2022: $1,744 · 2023: $1,870 · 2024: $1,744 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,780.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,738.76 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $963.93 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $669.38 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $645.87 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $605.48 | 2019-2025 | Farxiga, Airsupra |
| Amarin Pharma, INC. | $491.16 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $438.91 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $388.04 | 2019-2025 | Verquvo, Gardasil 9, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $367.30 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $334.00 | 2019-2024 | Veozah |
| Abbott Laboratories | $330.03 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Pfizer INC. | $287.75 | 2019-2025 | |
| Insulet Corporation | $237.64 | 2021-2025 | Omnipod |
| Mylan Specialty L.P. | $202.73 | 2019-2024 | Yupelri |
| Amgen INC. | $202.58 | 2021-2024 | Repatha, Otezla, Prolia |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Caldwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.